Can You Stay On GLP-1s Forever? A Look At Long-Term Use
Published on: May 27, 2025
Can You Stay on GLP-1s Forever featured image
Article author photo

Gloria Amor Arroyo

Bachelor of Science in Biomedical Sciences (2024). Current Bioinformatics MSc student (2025)

Article reviewer photo

Patience Mutandi

BSc. Medical Science (U. of Leeds), MBBS (CMU), MPH (U. of Chester)

Introduction

You’ve probably heard of Ozempic – it’s been all over the news lately as a popular weight loss drug. It has even been called a “game-changer” in tackling obesity. But what many people don’t realise is that the real story behind Ozempic’s success starts with a class of medications known as GLP-1 receptor agonists (or GLP-1s). These drugs mimic the action of a natural hormone, GLP-1, which helps control blood sugar levels and appetite.

While Ozempic (and Wegovy, which contains the same active ingredient, semaglutide) is now getting a lot of attention for its role in weight loss, GLP-1 drugs have been used for years to treat type 2 diabetes (T2D). In fact, that’s what they were originally developed for. T2D is a chronic condition that affects millions of people and can lead to serious complications if not managed properly. GLP-1 medications help by improving blood sugar control, supporting weight loss, and even offering protection against heart and kidney disease.

With their growing popularity, especially for weight loss, a key question has emerged: Can you stay on GLP-1s forever? And just as important, should you? That’s precisely what this article will explore.

But before we explore the long-term picture, let’s take a closer look at how these medications actually work.

What is GLP-1?

When we say GLP-1 (glucagon-like peptide-1) medication, we actually refer to GLP-1 receptor analogues. In simple terms, this means that these medications mimic the GLP-1 hormone in the body.1 Think about it as a chemical messenger that transmits information in the body.  So the GLP-1 in the medications pretends to be natural GLP-1 and triggers the same effects. These include:1

Increasing insulin secretion

GLP-1 releases insulin (a hormone which, in turn, lowers sugar levels in the blood) from the pancreas. When insulin is faulty or your body doesn't react to it, sugar levels stay high in the blood, and diabetes is likely to happen. 

Inhibiting glucagon release

GLP-1 also suppresses glucagon, a hormone that normally signals the liver to release sugar into the bloodstream.

Slowing the emptying of the stomach

It slows the process of emptying the stomach, which helps control sugar spikes after meals and helps keep you full for longer (increases satiety). 

Reducing appetite

GLP1 binds to the hypothalamus, reducing appetite, which leads to a reduction in calorie intake.2

GLP-1 for obesity and diabetes

For T2D, GLP-1 helps lower blood sugar by:

  • Increasing insulin 
  • Decreasing glucagon 
  • Slowing how fast food leaves the stomach

This helps maintain stable blood sugar levels after meals. When it comes to obesity, GLP-1 also affects the brain by:

  • Reduce appetite
  • Increase feelings of fullness

As a result, people tend to eat less and gradually lose weight.

Types of GLP-1s

In the UK, several GLP-1 receptor agonists are available, primarily prescribed for T2D and, more recently, for weight management. 

Injectable

The most popular is semaglutide, available as Ozempic for diabetes and Wegovy for obesity. Semaglutide is administered as a once-weekly injection.

Liraglutide, sold as Victoza for diabetes and Saxenda for weight loss, is a daily injection and was one of the first GLP-1s widely used in the UK. 

Tablet

Rybelsus, a semaglutide that comes in the form of a pill used for T2D.

These medications are usually prescribed alongside lifestyle changes like improved diet and exercise, and access through the NHS is typically based on clinical need and eligibility, especially for weight loss purposes.

Long-term efficacy of GLP-1 therapy in diabetes

For people with T2D, GLP-1 medications are a great long-term option for keeping blood sugar under control. Clinical trials have shown that they consistently lower HbA1c, an important marker of average blood sugar, and that this effect holds steady over time.3 But the benefits go beyond just glucose control. Longer-acting versions like semaglutide and dulaglutide also help protect against major complications like heart attacks, strokes, and kidney problems, which is a big deal for those at higher cardiovascular risk.3 Unlike some other diabetes drugs, GLP-1s don’t seem to lose their effectiveness over time, and the body doesn’t build up a resistance to them. So, unless someone runs into side effects, there’s usually no issue with taking these medications long term.

Long-term efficacy of GLP-1 therapy in Obesity

The use of GLP-1 on obesity is a more debated topic. 

Overall, research has shown that after a while, weight loss plateaus in people taking GLP-1. For instance when taking Mounjaro, after 3 years weight loss plateaus.4 Similarly, the SELECT trial assessed semaglutide's (Ozempic’s) long-term effects and found that weight loss was sustained over four years.5

However, it is also interesting to see whether GLP-1’s effects on weight loss are sustained after stopping treatment. This is mainly because:

This makes people stop the treatment over time.

Several clinical trials and studies have evaluated this, and there seems to be a consensus – gaining some weight after stopping is likely to happen. 

For instance, a study shows that people on semaglutide regain weight after stopping treatment (from 17% weight loss to 5%).7 Moreover, in a randomised clinical trial study, some people were given the medication, and after some time, some people were switched to a placebo.8 People who continued on the medication lost an extra 8% weight, while the others gained 7% more. The same study was done for tirzepatide, and people who continued treatment lost an extra 5.5%, while those who didn't regained 14%.9

There are also studies exploring how to stop GLP-1 agonists while minimising the risk of regaining weight. A study showed that adding exercise while you’re on the medication can help maintain the weight once you quit.10 Moreover, another study showed that transitioning to affordable, generic diabetes/weight loss drugs helps maintain weight loss.11 Another preliminary study showed that tapering off the medication might reduce its effects and help maintain weight.12 This might be a good idea for people who have gained weight due to pregnancy, stopped smoking or are experiencing depression.

Safety over time

The most common side effects are gastrointestinal:3

  • Nausea
  • Vomiting
  • Diarrhea

But they usually occur early on or when you dose up and diminish with time. Other more serious  side effects are:

  • Pancreatitis 
  • Intestinal blockage or ileus 
  • Gastroparesis (stomach paralysis)

Gallbladder issues and rare cases of pancreatitis have been reported.

FAQs

Can I stay on GLP-1 medications forever?

Yes, many people, especially those with type 2 diabetes, use GLP-1s long-term with good results. As long as you're tolerating the medication and it's helping manage your condition, there's usually no need to stop unless advised by your doctor.

What happens if I stop taking a GLP-1 for weight loss?

It’s common to regain some weight after stopping, especially if no other changes are made. Your appetite can increase again, and your body might start to revert to its former weight. Working with a doctor on a plan to taper off or transition can help minimise rebound weight gain.

Are there risks with using GLP-1s long-term?

For most people, side effects like nausea or stomach issues go away over time. However, rare risks like pancreatitis, gallbladder problems, or intestinal issues have been reported. That’s why regular check-ins with your healthcare provider are important.

Summary

So, can you stay on GLP-1s forever? Technically, yes. As long as your body tolerates the medication and you’re not experiencing serious side effects, long-term use is safe and quite common, especially for people with T2D. These drugs help keep blood sugar under control and lower the risk of serious complications like heart disease and kidney issues. If it’s working for you and you feel good about it, there’s usually no reason to stop.

But when it comes to weight loss, it’s a bit more complicated. Many people lose a significant amount of weight in the first year or two, but it is normal to hit a plateau. At that point, some might consider stopping the medication, and yes, some weight regain is common after stopping. That doesn’t mean the drug didn't work; it just means your body is adjusting.

If you're thinking about coming off GLP-1s, it's important to do it under medical supervision. A doctor can help you taper off slowly to reduce the chances of side effects or rapid weight regain. They might also recommend transitioning to a different medication.

References

  1. Gupta V. Glucagon-like peptide-1 analogues: An overview. Indian J Endocrinol Metab [Internet]. 2013 [cited 2025 Apr 24]; 17(3):413–21. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712370/
  2. Popoviciu M-S, Păduraru L, Yahya G, Metwally K, Cavalu S. Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials. Int J Mol Sci [Internet]. 2023 [cited 2025 Apr 24]; 24(13):10449. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341852/
  3. Drucker DJ. Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity. Diabetes Care [Internet]. 2024 [cited 2025 Apr 24]; 47(11):1873–88. Available from: https://diabetesjournals.org/care/article/47/11/1873/156807/Efficacy-and-Safety-of-GLP-1-Medicines-for-Type-2
  4. Davis N, correspondent NDS. People using drug Mounjaro sustain weight loss over three years, trial finds. The Guardian [Internet]. 2025 Apr. 11 [cited 2025 Apr 24]; Society. Available from: https://www.theguardian.com/society/2025/apr/11/people-using-drug-mounjaro-sustain-weight-loss-over-three-years-trial-finds
  5. RPh DE. SELECT Trial: Weight Loss With Semaglutide Sustained Over 4 Years. MPR [Internet]. 2024 [cited 2025 Apr 24]. Available from: https://www.empr.com/home/news/select-trial-weight-loss-with-semaglutide-sustained-over-4-years/
  6. Do D, Lee T, Peasah SK, Good CB, Inneh A, Patel U. GLP-1 Receptor Agonist Discontinuation Among Patients With Obesity and/or Type 2 Diabetes. JAMA Netw Open [Internet]. 2024 [cited 2025 Apr 24]; 7(5):e2413172. Available from: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2819256
  7. Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab [Internet]. 2022 [cited 2025 Apr 24]; 24(8):1553–64. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542252/
  8. Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA [Internet]. 2021 [cited 2025 Apr 24]; 325(14):1414. Available from: https://jamanetwork.com/journals/jama/fullarticle/2777886
  9. Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin W-Y, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA [Internet]. 2024 [cited 2025 Apr 24]; 331(1):38. Available from: https://jamanetwork.com/journals/jama/fullarticle/2812936
  10. Jensen SBK, Blond MB, Sandsdal RM, Olsen LM, Juhl CR, Lundgren JR, et al. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial. eClinicalMedicine [Internet]. 2024 [cited 2025 Apr 24]; 69:102475. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10965408/
  11. Paddu NU, Lawrence B, Wong S, Poon SJ, Srivastava G. Weight maintenance on cost‐effective antiobesity medications after 1 year of GLP‐1 receptor agonist therapy: a real‐world study. Obesity [Internet]. 2024 [cited 2025 Apr 24]; 32(12):2255–63. Available from: https://onlinelibrary.wiley.com/doi/10.1002/oby.24177
  12. Secretariat E. Is coming off semaglutide slowly the key to preventing weight regain? EASO [Internet]. 2024 [cited 2025 Apr 24]. Available from: https://easo.org/is-coming-off-semaglutide-slowly-the-key-to-preventing-weight-regain/
Share

Gloria Amor Arroyo

Bachelor of Science in Biomedical Sciences (2024). Current Bioinformatics MSc student (2025)

arrow-right